| ILC (n = 131) | IDC (n = 133) | Total cases (n = 264) | P-value |
---|---|---|---|---|
Age (years) | 59 (35–87) | 55 (24–82) | 57 (24–87) | 0.001 |
Tumor size (cm) | 2.0 (0.2–9.0) | 1.5 (0.1–6.5) | 1.7 (0.1–9.0) | 0.006 |
T-stage | Â | Â | Â | Â |
   T1 | 75(58%) | 88 (66%) | 163 (62%) | 0.298 |
   T2 | 49 (38%) | 43 (32%) | 92 (35%) |  |
   T3 | 5 (4%) | 2 (2%) | 7 (3%) |  |
   T4 | 1 (1%) | 0 (0%) | 1 (0.5%) |  |
Tumor focality | Â | Â | Â | Â |
   Unifocal | 97 (75%) | 123 (93%) | 220 (84%) | <0.001 |
   Multifocal | 19 (15%) | 9 (7%) | 28 (11%) |  |
   Multicentric | 14 (11%) | 1 (1%) | 15 (6%) |  |
Histologic grade | Â | Â | Â | Â |
   Grade 1 | 40 (31%) | 32 (24%) | 72 (27%) | <0.001 |
   Grade 2 | 57 (44%) | 52 (39%) | 109 (41%) |  |
   Grade 3 | 17 (13%) | 48 (36%) | 65 (25%) |  |
   Unknown | 17 (13%) | 1 (1%) | 18 (7%) |  |
ER status | Â | Â | Â | Â |
   Positive | 121 (93%) | 96 (72%) | 217 (82) | <0.001 |
   Negative | 2 (2%) | 29 (22%) | 31 (12%) |  |
   Unknown | 8 (6%) | 8 (6%) | 16 (6%) |  |
PR status | Â | Â | Â | Â |
   Positive | 108 (82%) | 81 (61%) | 189 (72%) | <0.001 |
   Negative | 16 (12%) | 44 (33%) | 60 (23%) |  |
   Unknown | 7 (5%) | 8 (6%) | 15 (6%) |  |
Her-2/neu | Â | Â | Â | Â |
   Positive | 13 (10%) | 35 (26%) | 48 (18%) | 0.003 |
   Negative | 106 (81%) | 87 (65%) | 193 (73%) |  |
   Unknown | 12 (9%) | 11 (8%) | 23 (9%) |  |
LVI | Â | Â | Â | Â |
   Positive | 20 (15%) | 41 (31%) | 61 (23%) | 0.005 |
   Negative | 109 (83%) | 92 (69%) | 201 (76%) |  |
   Unknown | 2 (2%) | 0 (0%) | 2 (1%) |  |